Amendment and Reply to Office Action Application No. <u>09/713,098</u> Attorney's Docket No. <u>DX01051Q (033347-013)</u> Page 2

## **CLAIM AMENDMENTS**

Claims 11, 12 and 15 are pending in this application prior to the amendments.

Claims 11 and 12 are being amended. Claims 21-22 are being added

After the amendments, claims 11, 12, 15 and 21-22 will be pending.

## **CLAIM LIST**

- 11. (Currently amended) A binding compound comprising an antigen binding site from an antibody which specifically binds to a the polypeptide comprising the amino acid sequence of residues 1-30 or 286-470 of SEQ ID NO:2.
- 12. (Currently amended) The binding compound of Claim 11, wherein:
  - a) the antigen binding site is:
    - specifically immunoreactive with a the polypeptide of residues 1-30 or 286-470 of SEQ ID NO:2;
    - 2) raised against a purified or recombinantly produced human DC-STAMP; or
    - from a monoclonal antibody, Fab, or  $F(ab)_2$ ; or
  - b) the binding compound is:
    - 1) an antibody molecule:
    - 2) a polyclonal antiserum;
    - 3) detectably labeled;
    - 4) sterile; or
    - 5) in a buffered composition.
- 15. (Previously presented) A detection kit comprising:
  - a) the detectably labeled binding compound of Claim 12;
  - b) instructions for use; and
  - c) a compartment for reagents.
- 21. (New) The binding compound of Claim 11 wherein the antibody specifically binds to the polypeptide of residues 399-470 of SEQ ID NO:2.
- 22. (New) The binding compound of Claim 11 wherein the polypeptide is glycosylated.